Clinicopathological characteristics and treatment of young women with breast cancer in China: a nationwide multicenter 10-year retrospective study
- PMID: 33633974
- PMCID: PMC7882316
- DOI: 10.21037/gs-20-574
Clinicopathological characteristics and treatment of young women with breast cancer in China: a nationwide multicenter 10-year retrospective study
Abstract
Background: Breast cancer is currently the most common female malignancy in China. However, the clinical features and overall prognosis of young women diagnosed with this malignancy remain unclear. This study aimed to describe the clinicopathological characteristics of young patients (≤34 years of age) with breast cancer and explore the current treatment approaches used in China.
Methods: This was a hospital-based, multicenter, retrospective study of women with breast cancer across seven Chinese hospitals from 1999 to 2008. A total of 295 young (≤34 years of age) patients (research group) and 2,119 women aged 35 to 49 years (control group) were included in the study. Patient epidemiology, pre-operative examinations, clinical pathology, and treatment were analyzed.
Results: The percentage of young patients with breast cancer in the study group was 7.01%. These young women had a lower body mass index (BMI), a higher level of education, a lower number of previous births, and a lower history of breastfeeding than the control group (P<0.05). Increasingly, pre-operative use of ultrasound and magnetic resonance imaging are being used to diagnose breast cancer in young women in China. In young women with breast cancer, breast cancer not otherwise specified (NOS) was the primary pathology. The carcinoma in young women was more prone to lymph node metastasis, showed less progesterone receptor (PR) expression, and was more advanced than observed in the control group (P<0.05). We found that the number of young breast cancer patients undergoing breast-conserving surgery in China is increasing.
Conclusions: Young breast cancer patients display unique clinicopathological features, including tumors of a higher grade than those aged 35 years or older. As breast cancer is more aggressive in younger women, prevention and early diagnosis are critical, and new policies should be developed in line with these findings.
Keywords: Young age; breast cancer; clinicopathological characteristics; retrospective study.
2021 Gland Surgery. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/gs-20-574). The authors have no conflicts of interest to declare.
Figures


Similar articles
-
Comparison of Clinicopathological Features and Treatments between Young (≤40 Years) and Older (>40 Years) Female Breast Cancer Patients in West China: A Retrospective, Epidemiological, Multicenter, Case Only Study.PLoS One. 2016 Mar 31;11(3):e0152312. doi: 10.1371/journal.pone.0152312. eCollection 2016. PLoS One. 2016. PMID: 27031236 Free PMC article. Clinical Trial.
-
Magnetic resonance imaging characteristics of invasive breast cancer in women aged less than 35 years.Acta Radiol. 2015 Aug;56(8):924-32. doi: 10.1177/0284185114542365. Epub 2014 Jul 14. Acta Radiol. 2015. PMID: 25024441 Clinical Trial.
-
Breast cancer in young women from a low risk population in Nepal.Asian Pac J Cancer Prev. 2013;14(9):5095-9. doi: 10.7314/apjcp.2013.14.9.5095. Asian Pac J Cancer Prev. 2013. PMID: 24175782
-
Breast cancer under age 40: a different approach.Curr Treat Options Oncol. 2015 Apr;16(4):16. doi: 10.1007/s11864-015-0334-8. Curr Treat Options Oncol. 2015. PMID: 25796377 Review.
-
Breast cancer in young women.Ginekol Pol. 2016;87(9):659-663. doi: 10.5603/GP.2016.0062. Ginekol Pol. 2016. PMID: 27723074 Review.
Cited by
-
Application value of Neuman's nursing model in the perioperative period of radical mastectomy.Am J Transl Res. 2024 Sep 15;16(9):4928-4938. doi: 10.62347/UPBL4602. eCollection 2024. Am J Transl Res. 2024. PMID: 39398611 Free PMC article.
-
A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer.Oncologist. 2024 Jan 5;29(1):e15-e24. doi: 10.1093/oncolo/oyad160. Oncologist. 2024. PMID: 37279780 Free PMC article. Clinical Trial.
-
Establishment and verification of a nomogram to predict tumor-specific mortality risk in triple-negative breast cancer: a competing risk model based on the SEER cohort study.Gland Surg. 2022 Dec;11(12):1961-1975. doi: 10.21037/gs-22-650. Gland Surg. 2022. PMID: 36654948 Free PMC article.
-
Prognostic factor analysis and clinical significance of HER‑2‑positive breast cancers with negative lymph nodes and a tumor diameter ≤1 cm.Oncol Lett. 2023 Sep 28;26(5):491. doi: 10.3892/ol.2023.14078. eCollection 2023 Nov. Oncol Lett. 2023. PMID: 37854866 Free PMC article.
-
Adjuvant ovarian function suppression in premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a multi-center retrospective study.BMC Cancer. 2025 Apr 17;25(1):723. doi: 10.1186/s12885-025-14120-0. BMC Cancer. 2025. PMID: 40247248 Free PMC article.
References
-
- Desiris K, Dragoumis D, Assimaki A, et al. 51 Very Young Women (< 35 Years) with Primary Breast Cancer. a Single Institution Retrospective Analysis (2005-2009). Eur J Cancer 2012;48:S55 10.1016/S0959-8049(12)70119-3 - DOI
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials